Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 11, 1997, Pages 2484-2491

  Back, Nicole K T ^a   Berkhout, Ben ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

AMINO ACID SUBSTITUTION; ARTICLE; CELL TRANSFORMATION; DRUG RESISTANCE; ENZYME BINDING; ENZYME ISOLATION; GENETIC MANIPULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0030691001     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.11.2484     Document Type: Article

References (55)

1. Arts, E. J., J. Mak, L. Kleiman, and M. A. Wainberg. 1994. DNA found in human immunodeficiency virus type 1 particles may not be required for infectivity. J. Gen. Virol. 75:1605-1613.
2. Back, N. K. T., M. Nijhuis, W. Keulen, C. A. B. Boucher, B. B. Oude Essink, A. B. P. van Kuilenburg, A. H. Van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
3. Bakhanashvili, M., O. Avidan, and A. Hizi. 1996. Mutational studies of human immunodeficiency virus type 1 reverse transcriptase: the involvement of residues 183 and 184 in the fidelity of DNA synthesis. FEBS Lett. 391: 257-262.
4. Balzarini, J., H. Pelemans, A. Karlsson, E. De Clercq, and J.-P. Kleim. 1996. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 93:13152-13157.
5. Berkhout, B., and J. L. B. van Wamel. 1996. Role of the DIS hairpin in replication of human immunodeficiency virus type 1. J. Virol. 70:6723-6732.
6. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. L. Rouse, and J. M. Cameron. 1993. High level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine (3TC) in vitro is due to one amino acid substitution in the catalytic site of HIV-1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
7. Boyer, P. L., and S. H. Hughes. 1995. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 7:1624-1628.
8. Coates, J. A. V., N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36:733-739.
9. Coates, J. A. V., N. Cammack, H. J. Jenkinson, I. M. Mutton, B. A. Pearson, R. Storer, J. M. Cameron, and C. R. Penn. 1992. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob. Agents Chemother. 36:202-205.
10. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
11. Collin, M., and S. Gordon. 1994. The kinetics of human immunodeficiency virus reverse transcription are slower in primary human macrophages than in a lymphoid cell line. Virology 200:114-120.
12. Delta Coordinating Committee. 1996. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348: 283-291.
13. Fan, N., K. B. Rank, D. E. Slade, S. M. Poppe, D. B. Evans, L. A. Kopta, R. A. Olmsted, R. C. Thomas, W. G. Tarpley, and S. K. Sharma. 1996. A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Biochemistry 35:9737-9745.
14. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. A. B. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
15. Gao, W.-Y., D. G. Johns, S. Chokekijchai, and H. Mitsuya. 1995. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 92:8333-8337.
16. Gao, W. Y., A. Cara, R. C. Gallo, and F. Lori. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type I replication. Proc. Natl. Acad. Sci. USA 90:8925-8928.
17. Giacca, M., S. Borella, F. Calderazzo, L. C. Bianchi, P. D'Agaro, C. Rampazzo, V. Bianchi, and P. Reichard. 1996. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3′-azido-3′-deoxythymidine on HIV type 1 infection in vitro. AIDS Res. Hum. Retroviruses 12:677-682.
18. Giacca, M., S. Zanussi, M. Comar, C. Siminelli, E. Vaccher, P. de Paoli, and U. Tirelli. 1996. Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. J. Infect. Dis. 174:204-209.
19. Hammer, S. M., D. A. Katzen, M. D. Hughes, H. Gundacker, R. T. Schooley, R. H. Haubrich, W. K. Henry, M. M. Lederman, J. P. Phair, M. Niu, M. S. Hirsch, and T. C. Merigan for the AIDS Clinical Trials Group Study 175 Study Team. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4+ cell counts from 200 to 500 per cubic millimeter. N. Engl. J. Med. 335:1081-1090.
20. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
21. Ji, X., G. J. Klarmann, and B. D. Preston. 1996. Effect of human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein on HIV-1 reverse transcriptase activity in vitro. Biochemistry 35:132-143.
22. Keulen, W., N. K. T. Back, A. van Wijk, C. A. B. Boucher, and B. Berkhout. 1997. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of the human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 71:3346-3350.
23. Keulen, W., M. Nijhuis, R. Schuurman, B. Berkhout, and C. A. B. Boucher. 1997. Reverse transcriptase fidelity and HIV-1 variation. Science 275:229.
24. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
25. Lori, F., and R. C. Gallo. 1995. Hydroxyurea and AIDS: an old drug finds a new application? AIDS Res. Hum. Retroviruses 11:1149-1151.
26. Lori, F., A. Malykh, A. Cara, D. Sun, J. N. Weinstein, J. Lisziewicz, and R. C. Gallo. 1994. Hydroxyurea as an inhibitor of human immunodeficiency virus type I replication. Science 266:801-805.
27. Luciw, P. 1996. Human immunodeficiency viruses and their replication. p. 1881-1952. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology. Lippincott-Raven Publishers, Philadelphia, Pa.
28. Malley, S. D., J. M. Grange, F. Hamedi-Sangsari, and J. R. Vila. 1994. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc. Natl. Acad. Sci. USA 91:11017-11021.
29. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
30. McKeating, J. A., A. McKnight, and J. P. Moore. 1991. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J. Virol. 65:852-860.
31. Meyerhans A., J.-P. Vartanian, C. Hultgren, U. Plikat, A. Karlsson, L. Wang, S. Eriksson, and S. Wain-Hobson. 1994. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J. Virol. 68:535-540.
32. Moore, J. P., J. A. McKeating, R. A. Weiss, and Q. J. Sattentau. 1990. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250:1139-1142.
33. Najera, I., A. Holguin, M. E. Quinones-Mateu, M. A. Munoz-Fernandez, R. Najera, C. Lopez-Galindez, and E. Domingo. 1995. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69:23-31.
34. O'Brien, W. A., A. Namazi, H. Kalhor, S.-H. Mao, J. A. Zack, and I. S. Y. Chen. 1994. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J. Virol. 68:1258-1263.
35. Olmsted, R. A., D. E. Slade, L. A. Kopta, S. M. Poppe, T. J. Poel, S. W. Newport, K. B. Rank, C. Biles, R. A. Morge, T. J. Dueweke, Y. Yagi, D. L. Romero, R. C. Thomas, S. K. Sharma, and W. G. Tarpley. 1996. (Alkylamino)piperidine bis(heteroaryl) piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1 IIIB with reduced replication phenotypes. J. Virol. 70: 3698-3705.
36. Oude Essink, B. B., A. T. Das, and B. Berkhout. 1996. HIV-1 reverse transcriptase discriminates against non-self tRNA primers. J. Mol. Biol. 264:243-254.
37. 36a. Oude Essink, B. B., N. K. T. Back, and B. Berkhout. 1997. Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase. Nucleic Acids Res. 25:3212-3217.
38. Pandey, V. N., N. Kaushik, N. Rege, S. G. Sarafianos, P. N. S. Yadav, and M. J. Modak. 1996. Role of methionine 184 of human immunodeficiency virus type 1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry 35:2168-2179.
39. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
40. + cells per millimeter. N. Engl. J. Med. 335:1099-1106.
41. Schinazi, R. F., C. K. Chu, A. Peck, A. McMillan, R. Mathis, D. Cannon, L.-S. Jeong, J. W. Beach, W.-B. Choi, S. Yeola, and D. C. Liotta. 1992. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob. Agents Chemother. 3:672-676.
42. Schooley, R. T., C. Ramirez-Ronda, J. M. A. Lange, D. A. Cooper, J. Lavelle, L. Lefkowitz, M. Moore, B. A. Larder, M. St. Clair, J. W. Mulder, R. McKinnis, K. N. Pennington, P. R. Harrigan, I. Kinghorn, H. Steel, and J. F. Rooney. 1996. Virological and immunological benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared to ziduvudine. J. Infect. Dis. 173:1354-1366.
43. Schuurman, R., M. Nijhuis, R. Van Leeuwen, P. Schipper, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, S. Kwok, J. Sninsky, and C. A. B. Boucher. 1995. Rapid changes in human immunodeficiency virus type I RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
44. Schwartz, O., V. Marechal, O. Danos, and J.-M. Heard. 1995. Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transription in the infected cell. J. Virol. 69:4053-4059.
45. Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67:31-40.
46. Tanchou, V., C. Gabus, V. Rogemond, and J.-L. Darlix. 1995. Formation of stable and functional HIV-1 nucleoprotein complexes in vitro. J. Mol. Biol. 252:563-571.
47. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
48. Trono, D. 1992. Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J. Virol. 66:4893-4900.
49. Wainberg, M. A., W. C. Drosopoulos, H. Salomon, M. Hsu, G. Borkow, M. A. Parniak, Z. Gu, Q. Song, J. Manne, S. Islam, G. Castriota, and V. R. Prasad. 1996. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:1282-1285.
50. Waingberg, M. A., H. Salomon, Z. Gu, J. S. G. Montaner, T. P. Cooley, R. McCaffrey, J. Ruedy, H. M. Hirst, N. Cammack, J. Cameron, and W. Nicholson. 1995. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9:351-357.
51. Wakefield, J. K., S. A. Jablonski, and C. D. Morrow. 1992. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J. Virol. 66:6806-6812.
52. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-126.
53. Yoshioka, A., S. Tanaka, O. Hiaraoka, Y. Koyama, Y. Hirota, D. Ayusawa, T. Seno, C. Garrett, and Y. Wataya. 1987. Deoxyribonucleoside triphosphate imbalance: 5-fluro-deoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J. Biol. Chem. 262: 8235-8241.
54. Zack, J. A., S. J. Arrigo, S. R. Weitsman, A. S. Go, A. Haislip, and I. S. Y. Chen. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-222.
55. Zhang, H., G. Dornadula, and R. J. Pomerantz. 1996. Endogenous reverse transcriptiom of human immunodeficiency virus type 1 in physiological microenvironments: an important stage for viral infection of nondividing cells. J. Virol. 70:2809-2824.